CVS Reintroduces Zepbound: What You Need to Know About the New Coverage

In 2026, CVS Caremark announced that it will restore coverage of Eli Lilly’s Zepbound (tirzepatide) on many of its commercial formularies. The change is scheduled to take effect on October 1, 2026, when Zepbound returns as an additional preferred option for weight management. CVS Caremark also added coverage for Lilly’s oral GLP-1 medication Foundayo on an earlier date.

This article explains the background of the coverage change, why Zepbound was previously removed, and what the restoration may mean for patients. It is for general informational purposes only. Actual coverage depends on the specific health plan, employer decisions, and individual circumstances. Always verify details with the insurance plan and healthcare provider.

Why Zepbound Coverage Was Previously Stopped

In mid-2025, CVS Caremark removed Zepbound from its preferred commercial formulary status, effective around July 1, 2025. At the same time, it designated Novo Nordisk’s Wegovy (semaglutide) as the preferred GLP-1 medication for obesity on many standard formularies.

The primary reason cited for the change was cost management. CVS Caremark stated that it had negotiated more favorable pricing terms with Novo Nordisk, allowing it to prefer Wegovy in an effort to control spending on the high-demand GLP-1 class. The decision applied mainly to the weight-management indication and did not affect coverage of Lilly’s related diabetes medication Mounjaro in the same way.

The exclusion led to significant patient and clinician feedback. Many individuals reported being required to switch medications, and some raised concerns that the two drugs were not fully interchangeable due to differences in active ingredients, approved uses (including Zepbound’s indication for obstructive sleep apnea), and individual response. A class-action challenge was also filed related to the formulary decision.

The 2026 Restoration of Coverage

Following further negotiations with manufacturers, CVS Caremark announced in May 2026 that it would reinstate Zepbound as a preferred option on its standard commercial formulary templates beginning October 1, 2026. The company indicated that the updated agreements with both Lilly and Novo Nordisk were expected to generate additional savings across the weight-management category for plan sponsors.

Under the new arrangement, both Zepbound and Wegovy are positioned as preferred options on many plans that cover obesity medications. Eligible commercially insured patients may have access to lower copays (reported in some announcements as potentially as low as $25 per month when manufacturer savings programs apply), though exact costs depend on the individual plan design, deductible status, and prior authorization requirements.

What This Means for Patients

• Timing: Zepbound coverage restoration is set for October 1, 2026, on applicable CVS Caremark commercial formularies. Individual employers and health plans decide whether to adopt the standard template and whether to cover weight-loss medications at all.
• Prior Authorization: Most plans that cover Zepbound continue to require prior authorization and documentation of medical criteria (such as BMI thresholds and related conditions).
• Self-Pay Options Remain Relevant: Patients whose plans still exclude weight-loss coverage, or who face high out-of-pocket costs, may continue to explore manufacturer self-pay programs such as LillyDirect.
• Plan-Specific Verification: Coverage is not automatic. Patients should check their specific formulary, contact their plan, and work with their prescriber to confirm eligibility and any required steps.

Practical Steps for Patients

1. Review the current formulary for your specific health plan (often available through the insurer’s website or member portal).
2. Contact the insurance plan or pharmacy benefit manager to confirm whether Zepbound will be covered starting in October 2026 and what the expected cost-sharing will be.
3. Discuss the coverage change with the prescribing healthcare provider, including any prior authorization documentation that may be needed.
4. Compare potential insurance costs with current self-pay options if coverage remains limited or unavailable.
5. Keep records of all communications regarding coverage.

Important Considerations

Formulary decisions can continue to evolve. Employer-sponsored plans often have flexibility in which medications they cover and under what conditions. Prior authorization criteria, step therapy requirements, and cost-sharing amounts vary widely. Patients currently using Zepbound through other pathways (such as self-pay or different insurance) should plan ahead for the October 2026 transition if their plan is expected to adopt the restored coverage.

Disclaimer: This article is for general informational purposes only and does not constitute medical, insurance, or financial advice. Coverage decisions are made by individual health plans and employers. Zepbound is a prescription medication; only a qualified healthcare provider can determine whether it is appropriate. Always verify the most current formulary status, eligibility requirements, and costs directly with your insurance plan, pharmacy, and healthcare provider.